**Dosage Forms**

- Solution, Injection: 10 mg/ml, 20 mg/mL (25 mL), 100 mg/ml

- Intrathecal injection, liposomal: 50 mg/5ml

**Administration**- Rapid intravenous infusion, infuse over 1 to 3 hours intravenously or subcutaneously or intrathecally.

**Storage**- Store at room temperature.

**Dosing: Adult**

- Acute lymphoblastic leukemia (off-label dosing):

- Induction regimen, relapsed or refractory- Administer 3,000 mg/sq.meter of cytarabine over 3 hours by intravenous infusion daily for five days in combination with idarubicin for three days.
- Dose-intensive regimen- 3,000 mg/sq.meter of cytarabine over 2 hours by intravenous infusion. This dose is to be given every 12 hours on days 2 and 3 (4 doses/cycle) of even-numbered cycles in combination with methotrexate.

- Acute myeloid leukemia (remission induction chemotherapy):

- Administer standard dose 100 mg/sq.meter/day of cytarabine by continuous intravenous infusion for 7 days or give 200 mg/sq.meter/day by continuous intravenous infusion for 7 days(as 100 mg/m2 over 12 hours every 12 hours).

- Acute myeloid leukemia consolidation therapy (off-label use):

- 5+2 regimen: Administer 100 mg/sq.meter/day of cytarabine for five days by intravenous infusion in combination with daunorubicin or idarubicin, or mitoxantrone.

- Acute myeloid leukemia salvage treatment (off-label use):

- CLAG-M regimen: Administer 2,000 mg/sq.meter/day of cytarabine by intravenous infusion over 4 hours for five days in combination with cladribine, G-CSF, and mitoxantrone.

- Acute promyelocytic leukemia consolidation therapy (off-label use):

- First consolidation course: Administer 200 mg/sq.meter/day of cytarabine by intravenous infusion for seven days in combination with daunorubicin.
- Second consolidation course:

- If age is ≤60 years and low risk (WBC <10,000/cubic mm), then administer 1,000 mg/sq.meter of cytarabine every 12 hours for four days (8 doses) by intravenous infusion.
- If age is <50 years and high risk (WBC ≥10,000/cubic mm), then administer 2,000 mg/sq.meter of cytarabine every 12 hours for five days (10 doses) by intravenous infusion.
- If age is 50 to 60 years and high risk (WBC ≥10,000/cubic mm), then administer 1500 mg/sq.meter of cytarabine every 12 hours for five days (10 doses) by intravenous infusion.
- If age is >60 years and high risk (WBC ≥10,000/cubic mm) then administer 1,000 mg/sq.meter every 12 hours for four days (8 doses) by intravenous infusion.

- Acute promyelocytic leukemia induction (off-label dosing):

- Administer 200 mg/sq.meter/day of cytarabine by continuous intravenous infusion for seven days, beginning on the third day of treatment in combination with tretinoin and daunorubicin.